Barclays’s Exact Sciences EXAS Stock Holding History

Barclays’s Portfolio EXAS Stock Details EXAS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-48,000	Closed	-$3.27M	–	5334
2024 Q3	$3.27M	Buy	+48,000	New	+$2.71M	﹤0.01%	2448
2024 Q2	–	Sell	-63,000	Closed	-$4.35M	–	5007
2024 Q1	$4.35M	Buy	63,000 +53,000	+530%	+$3.35M	﹤0.01%	1963
2023 Q4	$740K	Sell	10,000 -136,000	-93%	-$8.91M	﹤0.01%	3645
2023 Q3	$9.96M	Buy	+146,000	New	+$12.4M	0.01%	998
2022 Q1	–	Sell	-78,000	Closed	-$6.07M	–	5147
2021 Q4	$6.07M	Buy	78,000 +20,000	+34%	+$1.77M	﹤0.01%	1565
2021 Q3	$5.54M	Buy	58,000 +900	+2%	+$95K	﹤0.01%	1557
2021 Q2	$7.1M	Sell	57,100 -17,200	-23%	-$2.05M	﹤0.01%	1379
2021 Q1	$9.79M	Buy	74,300 +46,300	+165%	+$6.34M	0.01%	1094
2020 Q4	$3.71M	Sell	28,000 -3,300	-11%	-$399K	﹤0.01%	1737
2020 Q3	$3.19M	Hold	31,300	–	–	﹤0.01%	1717
2020 Q2	$2.72M	Sell	31,300 -87,700	-74%	-$7.01M	﹤0.01%	1838
2020 Q1	$6.9M	Sell	119,000 -45,200	-28%	-$3.67M	0.01%	1232
2019 Q4	$15.2M	Buy	164,200 +27,800	+20%	+$2.44M	0.01%	1113
2019 Q3	$12.3M	Buy	136,400 +41,900	+44%	+$4.77M	0.01%	1158
2019 Q2	$11.2M	Sell	94,500 -102,400	-52%	-$10.3M	0.01%	1286
2019 Q1	$17.1M	Sell	196,900 -45,500	-19%	-$3.87M	0.01%	934
2018 Q4	$15.3M	Sell	242,400 -171,900	-41%	-$11.8M	0.01%	908
2018 Q3	$32.7M	Buy	414,300 +203,300	+96%	+$13.3M	0.02%	605
2018 Q2	$12.6M	Buy	211,000 +117,800	+126%	+$6.34M	0.01%	1070
2018 Q1	$3.76M	Buy	93,200 +37,500	+67%	+$1.83M	﹤0.01%	1852
2017 Q4	$2.93M	Sell	55,700 -132,300	-70%	-$7.06M	﹤0.01%	2091
2017 Q3	$8.86M	Buy	188,000 +87,300	+87%	+$3.51M	0.01%	1129
2017 Q2	$3.56M	Buy	100,700 +44,300	+79%	+$1.37M	﹤0.01%	1737
2017 Q1	$1.33M	Sell	56,400 -11,800	-17%	-$234K	﹤0.01%	2463
2016 Q4	$911K	Buy	68,200 +37,900	+125%	+$612K	﹤0.01%	2834
2016 Q3	$563K	Buy	30,300 +6,900	+29%	+$122K	﹤0.01%	3120
2016 Q2	$287K	Buy	23,400 +5,600	+31%	+$42.2K	﹤0.01%	3658
2016 Q1	$107K	Sell	17,800 -14,700	-45%	-$94K	﹤0.01%	4301
2015 Q4	$293K	Sell	32,500 -3,200	-9%	-$29.8K	﹤0.01%	3606
2015 Q3	$607K	Sell	35,700 -2,500	-7%	-$57.4K	﹤0.01%	3183
2015 Q2	$1.11M	Buy	38,200 +4,000	+12%	+$100K	﹤0.01%	2799
2015 Q1	$752K	Sell	34,200 -500	-1%	-$12.7K	﹤0.01%	3232
2014 Q4	$937K	Buy	34,700 +17,200	+98%	+$419K	﹤0.01%	3276
2014 Q3	$333K	Buy	17,500 +7,800	+80%	+$143K	﹤0.01%	4312
2014 Q2	$165K	Sell	9,700 -128,200	-93%	-$1.77M	﹤0.01%	4990
2014 Q1	$1.93M	Buy	137,900 +100,400	+268%	+$1.36M	﹤0.01%	2589
2013 Q4	$413K	Buy	37,500 +15,300	+69%	+$176K	﹤0.01%	4288
2013 Q3	$244K	Sell	22,200 -51,700	-70%	-$663K	﹤0.01%	4842
2013 Q2	$1.03M	Buy	+73,900	New	+$803K	﹤0.01%	3312

Other funds holding EXAS

VanEck Associates New York $133B AUM 72.99% 1-Year Est. Return

Wealth Enhancement Advisory Services Plymouth, Minnesota $59.8B AUM 29.42% 1-Year Est. Return

PRS

Pinkerton Retirement Specialists Coeur D Alene, Idaho $1.1B AUM 30.57% 1-Year Est. Return

PWMAG

Pinnacle Wealth Management Advisory Group Red Bank, New Jersey $1.46B AUM 22.77% 1-Year Est. Return

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

HNB

Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

Broadwater Capital Boston, Massachusetts $138M AUM 28.86% 1-Year Est. Return

Barclays's EXAS Position: Q1 2026 in Review

Barclays sold out of Exact Sciences (EXAS) in Q1 2026, closing a stake of 191,743 shares — an estimated $19.5M sold.

Barclays first reported a position in EXAS in Q2 2013 and held it in 51 quarters. The position peaked at $23.7M in Q2 2025. 7 funds tracked by Wall St. Rank hold EXAS as of Q1 2026.

Barclays reported no remaining Exact Sciences position as of Q1 2026 after selling out during the quarter.
Barclays sold 191,743 Exact Sciences shares in Q1 2026, an estimated $19.5M.
Barclays first reported a position in Exact Sciences in Q2 2013 and held it in 51 quarters.
Barclays's Exact Sciences position peaked at $23.7M in Q2 2025.
7 funds tracked by Wall St. Rank held Exact Sciences as of Q1 2026.

Based on Barclays's 13F filing for Q1 2026, filed 15 May 2026.